Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation
R Stone, S Mandrekar, B Sanford… - NEW ENGLAND …, 2017 - art.torvergata.it
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We
conducted a phase 3 trial to determine whether the addition of midostaurin-an oral …
conducted a phase 3 trial to determine whether the addition of midostaurin-an oral …
[PDF][PDF] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford… - N Engl J …, 2017 - beta.legeforeningen.no
BACKGROUND Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar… - New England …, 2017 - mayoclinic.elsevierpure.com
BACKGROUND Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin-an …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin-an …
[HTML][HTML] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford… - The New England …, 2017 - ncbi.nlm.nih.gov
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
[引用][C] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation
RM Stone, SJ Mandrekar, BL Sanford… - New England Journal …, 2017 - cir.nii.ac.jp
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar… - The New England …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin-an …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin-an …
[PDF][PDF] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford, K Laumann… - N Engl J …, 2017 - legeforeningen.no
BACKGROUND Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
RM Stone, SJ Mandrekar, BL Sanford… - The New England …, 2017 - europepmc.org
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin-an …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin-an …
Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford… - The New England …, 2017 - research.monash.edu
BACKGROUND Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin-an …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin-an …